As of 2025-12-18, the Intrinsic Value of SkinBioTherapeutics PLC (SBTX.L) is 3.75 GBP. This SBTX.L valuation is based on the model Discounted Cash Flows (EBITDA Exit 5Y). With the current market price of 13.50 GBP, the upside of SkinBioTherapeutics PLC is -72.20%.
The range of the Intrinsic Value is 2.92 - 5.84 GBP
Based on its market price of 13.50 GBP and our intrinsic valuation, SkinBioTherapeutics PLC (SBTX.L) is overvalued by 72.20%.
| Range | Selected | Upside | |
| a | |||
| DCF (Growth 5y) | (65.22) - (15.52) | (24.77) | -283.5% |
| DCF (Growth 10y) | (12.37) - (45.19) | (18.53) | -237.3% |
| DCF (EBITDA 5y) | 2.92 - 5.84 | 3.75 | -72.2% |
| DCF (EBITDA 10y) | 4.72 - 10.83 | 6.53 | -51.6% |
| Fair Value | -1.09 - -1.09 | -1.09 | -108.09% |
| P/E | (2.10) - (3.03) | (2.53) | -118.8% |
| EV/EBITDA | 1.22 - 1.38 | 1.29 | -90.5% |
| EPV | 4.94 - 6.07 | 5.50 | -59.2% |
| DDM - Stable | (3.09) - (17.43) | (10.26) | -176.0% |
| DDM - Multi | (4.02) - (17.71) | (6.56) | -148.6% |
| Market Cap (mil) | 43.02 |
| Beta | 0.86 |
| Outstanding shares (mil) | 3.19 |
| Enterprise Value (mil) | 39.24 |
| Market risk premium | 5.98% |
| Cost of Equity | 7.04% |
| Cost of Debt | 9.03% |
| WACC | 7.07% |